New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 22, 2014
10:23 EDTNTLS, SAM, SN, IVR, CTIC, CFN, TSO, ARCP, BCEI, WYHigh option volume stocks
High option volume stocks: WY CFN SN BCEI CTIC SAM ARCP IVR NTLS TSO
News For WY;CFN;SN;BCEI;CTIC;SAM;ARCP;IVR;NTLS;TSO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
December 9, 2014
08:14 EDTTSOTesoro Logistics accelerates timeline to reach $1B of EBITDA to 2017
Subscribe for More Information
08:13 EDTTSOTesoro expects to exceed 2014 improvement targets by over 30%
Tesoro (TSO) and Tesoro Logistics (TLLP) will host their annual analyst and investor day and the companies will provide details on the specific initiatives underway which will drive growth and create value for shareholders and unitholders. They will also provide a full-year 2015 financial outlook and detailed longer-term financial goals. "I am proud to report that in 2014 we have not only met, but we expect to exceed our targets by 30%. "In 2015, we expect to continue this momentum and deliver over $550M of additional improvements which will significantly increase shareholder value by capitalizing on our strong position on the West Coast, capturing margin improvements across our value chain and growing our logistics business," said Greg Goff, Tesoro President and CEO.
06:39 EDTWYNorbord, Ainsworth merger positive for Weyerhaeuser, says Citigroup
Citigroup views yesterday's merger announcement from Norbord and Ainsworth Lumber as positive for Weyerhaeuser (WY) and the oriented strand board market. Citi expects positive OSB earnings momentum for Weyerhaeuser as prices rebound in 2015-2016. Shares were up 58c yesterday to $36.11. Shares of Louisiana-Pacific (LPX), which attempted to acquire Ainsworth in 2013, rallied $1.33 to $16.83.
05:56 EDTCTICCTI BioPharma presents Pacritinib data at ASH meeting
Subscribe for More Information
December 8, 2014
10:30 EDTSNSanchez Energy downgraded to Market Perform at BMO Capital (pre-open)
Pre-open, BMO Capital downgraded Sanchez Energy to Market Perform from Outperform based on leverage concerns.
08:31 EDTCFNBecton Dickinson and CareFusion sets date for special meeting in proposed merger
Becton, Dickinson (BDX) and CareFusion (CFN) announced that CareFusion expects to hold a special meeting on January 21, 2015 for CareFusion stockholders to consider and vote upon the proposed merger of CareFusion and BD. As previously announced on October 5, 2014, BD and CareFusion entered into a definitive agreement pursuant to which BD would acquire CareFusion in a stock and cash transaction. CareFusion stockholder approval is a condition to the merger. In addition to CareFusion stockholder approval, the proposed acquisition remains subject to certain other conditions and approvals, including approval of the proposed acquisition by the European Commission under the European Union Merger Regulation. CareFusion has fixed the close of business on December 18, 2014 as the record date for the purpose of determining the stockholders who are entitled to notice of, and to vote at, the special meeting.
08:13 EDTCFNCareFusion announces agreement with Medacist
Subscribe for More Information
07:40 EDTBCEIMany E&P target prices lowered at SunTrust
Subscribe for More Information
December 7, 2014
14:25 EDTCTICCTI BioPharma announces analysis of kinase inhibition by pacritinib
CTI BioPharma announced that an analysis of kinase inhibition by pacritinib, a next generation oral multikinase inhibitor in Phase 3 clinical development, demonstrated a unique kinome profile among agents in development for myelofibrosis and suggests potential therapeutic benefit across a spectrum of blood-related cancers. Researchers presented the findings from this analysis at the 56th American Society of Hematology Annual Meeting and Exposition held December 6-9 in San Francisco, CA."The kinome profile of pacritinib shown in this analysis highlights how pacritinib is different from other JAK inhibitors that are currently on the market and in development for myelofibrosis," said Srdan Verstovsek, M.D., Ph.D., Director, Clinical Research Center for MPNs at The University of Texas MD Anderson Cancer Center and principal investigator for the Phase 3 PERSIST-2 trial of pacritinib. "One of the findings observed in clinical trials to date is the lack of myelosuppression seen with other treatments. Pacritinib's potent inhibition of FLT3, c-fms, IRAK1 and c-kit, all critical targets in hematologic malignancies, highlights its potential therapeutic utility in other indications, such as AML, MDS, CMML and CLL." The in vitro profiling of pacritinib across a panel of kinases showed the inhibition of all members of the JAK/FLT pathways, with the exception of JAK1. The JAK/FLT pathways are frequently dysregulated in many types of cancers. Additionally, pacritinib was found to inhibit the kinases c-fms and IRAK1. Disruption in the c-fms and IRAK1 pathways have been indicated to be involved in acute myeloid leukemia, myelodysplastic syndrome, chronic myelomonocytic leukemia and chronic lymphocytic leukemia. CTI believes the clinical efficacy and reduced myelosuppression seen in Phase 2 trials of pacritinib in patients with myelofibrosis is also likely attributable to this unique kinase inhibition profile. "These data not only demonstrate the unique attributes of pacritinib compared to other marketed agents or agents in development for the treatment of myelofibrosis, many of which have activity against JAK1, but also show the potential for broader use in other blood-related cancers," said Jack Singer, M.D., Executive Vice President, Global Medical and Translational Medicine at CTI and lead author of the analysis. "We are excited to pursue additional indications, such as AML, MDS, CMML and CLL, all of which are currently being evaluated in Phase 2 clinical trials, so we can potentially offer these patients an effective and less toxic treatment option."
14:10 EDTCTICAmerican Society of Hematology to hold a meeting
Subscribe for More Information
14:08 EDTCTICCTI BioPharma to hold a cocktail reception
Subscribe for More Information
December 5, 2014
06:44 EDTWYWeyerhaeuser to host investor meeting
Subscribe for More Information
December 4, 2014
16:57 EDTBCEIIntegrated Core Strategies reports 6.4% passive stake in Bonanza Creek
10:36 EDTSNOptions with increasing implied volatility
Subscribe for More Information
10:08 EDTTSOOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:23 EDTCTICOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Avago (AVGO), up 7.2%... Kroger (KR), up 3.1%... Rite Aid (RAD), up 3.1%... Sears Holdings (SHLD), up 2.3%. ALSO HIGHER: Array Biopharma (ARRY), up 24% after reaching a definitive agreement with Novartis (NVS) to regain full worldwide rights to binimetinib... Hawaiian Electric (HE), up 13.5% following merger announcement with NextEra Energy (NEE)... SinoCoking Coal (SCOK), up 14.2% after beginning construction of second aboveground Syngas facility... Plug Power (PLUG), up 12.3% after announcing $20M ReliOn fuel cell contract... Mobileye (MBLY), up 3.4% after being upgraded to Buy from Hold at Deutsche Bank... CTI BioPharma (CTIC), up 3.6% following $15M payment from Teva for TRISENOX... TASER (TASR), up 3% after receiving multiple orders of AXON body cameras. DOWN AFTER EARNINGS: Barnes & Noble (BKS), down 7.6%... Express (EXPR), down 11.3%... Toronto-Dominion Bank (TD), down 1.4%... Toro Company (TTC), down 1.1%... Aeropostale (ARO), down 14.1%. ALSO LOWER: Kindred Biosciences (KIN), down 29.3% after announcing that it will discontinue its AtoKin study... UTi Worldwide (UTIW), down 13% after saying that there are no current talks with DSV A/S... Agree Realty (ADC), down 3.7% after 2.1M share Spot Secondary priced at $29.90.
08:48 EDTTSOTesoro initiated with a Buy at Tudor Pickering
Subscribe for More Information
06:24 EDTARCPAmerican Realty to receive $60M settlement from RCS Capital
Subscribe for More Information
06:13 EDTARCPRCS Capital announces agreement to settle litigation with American Realty
Subscribe for More Information
05:30 EDTCTICCTI BioPharma receives $15M payment from Teva for TRISENOX
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use